98%
921
2 minutes
20
Objective: Multidisciplinary care of chronic limb threatening ischemia (CLTI) through specialized CLTI teams has been associated with improved outcomes, including decreased major amputations. Our goal was to characterize CLTI teams and examine their association with outcomes in the Best Endovascular versus Surgical Therapy in Patients with CLTI (BEST-CLI) trial.
Methods: Responses from a previously described post-trial electronic survey were used to describe CLTI care providers and characterize centers based on the presence of a "formally defined team dedicated to the care of CLTI patients". Patient-level data were analyzed to determine the association of CLTI teams with outcomes. Primary outcomes were: (1) Major (above-ankle) amputation and (2) Major adverse limb event (MALE) or death from any cause. Secondary outcome was the High-Low amputation ratio (ratio of major amputations/minor amputations). Cox multivariable models were used to control for patient demographics, limb stage and revascularization type.
Results: The overall survey response rate was 20.2% with at least 1 response from 75% of enrolling sites. Among survey respondents, specialties identified most frequently as being among those primarily responsible for CLTI care at centers with CLTI teams were: revascularization specialists (vascular surgery, interventional cardiology or interventional radiology, 92%), podiatry (32%) and wound care (22%). Compared to centers without CLTI teams, podiatrists at CLTI team centers were more likely to have a primary role (32% vs 11%) and less likely to be unavailable (4% vs 22%) (P<0.001). Similarly, at centers with CLTI teams, wound care specialists were more likely to have a primary role (22% vs 8%) and less likely to be unavailable (4% vs 11%) (P=0.02). Effectiveness of teamwork among CLTI providers was described as "highly effective" in 71% of respondents with a CLTI team vs 29% without a team (P<0.001). In BEST-CLI, 110 centers (73%) could be classified based on availability of a CLTI team (31% team vs 69% no team), representing 83% of all enrolled patients (n=1,520). Patients treated at centers with a CLTI team had similar rates of unadjusted 1-year above-ankle amputation (7.9% team [95% CI 5.7%-10.7%] vs 12.1% no team [95% CI 10.1%-14.4%], P=0.07) and MALE or death (29% team [95% CI 25.1% -33.3%] vs 33% no team [95% CI 30.1% -36.2%], P=0.07). On multivariable analysis, presence of a CLTI team was independently associated with decreased major amputation (HR 0.60 [95% CI 0.42-0.86], p=0.005) but no significant difference in MALE or death (HR 0.89 [95% CI 0.74-1.06], p=0.2). The High-Low amputation ratio was lower at centers with CLTI teams (0.20, [95% CI 0.14-0.28]) compared to centers with no team (0.31 [95% CI 0.25-0.38]) (P=0.03) CONCLUSIONS: In the BEST-CLI trial, formally defined CLTI teams were associated with decreased risk of major amputation. This may be partially attributable to more effective communication and closer involvement between vascular specialists, podiatry and wound care providers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2025.08.028 | DOI Listing |
J Vasc Surg
August 2025
Brigham and Women's Hospital, Boston, MA, USA.
Objective: Multidisciplinary care of chronic limb threatening ischemia (CLTI) through specialized CLTI teams has been associated with improved outcomes, including decreased major amputations. Our goal was to characterize CLTI teams and examine their association with outcomes in the Best Endovascular versus Surgical Therapy in Patients with CLTI (BEST-CLI) trial.
Methods: Responses from a previously described post-trial electronic survey were used to describe CLTI care providers and characterize centers based on the presence of a "formally defined team dedicated to the care of CLTI patients".
Ann Vasc Surg
October 2025
Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK.
Background: Chronic limb-threatening ischemia (CLTI) presents significant challenges in both diagnosis and management, with a lack of standardized preoperative assessment and optimization frameworks. This study aimed to establish a contemporary consensus among vascular specialists on the perioperative care of CLTI patients across diverse health-care systems.
Methods: A modified Delphi methodology was used, involving iterative rounds of consultation with 42 expert vascular surgeons from the United Kingdom, Ireland, Australia, and New Zealand.
Age Ageing
June 2024
Faculty of Health, University of Plymouth, Plymouth, UK.
Peripheral artery disease (PAD) is the lower limb manifestation of systemic atherosclerotic disease. PAD may initially present with symptoms of intermittent claudication, whilst chronic limb-threatening ischaemia (CLTI), the end stage of PAD, presents with rest pain and/or tissue loss. PAD is an age-related condition present in over 10% of those aged ≥65 in high-income countries.
View Article and Find Full Text PDFAnn Vasc Surg
October 2024
Division of Vascular Surgery, Department of Surgery, University of Washington, Seattle, WA. Electronic address:
Multidisciplinary teams are necessary to treat complex patients with chronic limb-threatening ischemia (CLTI). The need for adequate wound care and control of comorbid conditions cannot be accomplished by the vascular specialist alone. Numerous specialties have a role in this group to include surgical podiatrists, orthopedic surgery, plastic and reconstructive surgery endocrinology, and wound care.
View Article and Find Full Text PDFJ Vasc Surg
April 2024
Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Objectives: There has been significant variability in practice patterns and equipoise regarding treatment approach for chronic limb-threatening ischemia (CLTI). We aimed to assess treatment preferences of Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) investigators prior to and following the trial.
Methods: An electronic 60-question survey was sent to 1180 BEST-CLI investigators in 2022, after trial conclusion and before announcement of results.